UPSTREAM BIO, INC. Increase (Decrease) in Prepaid Expense and Other Assets
UPSTREAM BIO, INC. (UPB) reported Increase (Decrease) in Prepaid Expense and Other Assets of $7.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$3.14M, a 264.30% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $11.05M, a 19.64% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$6.29M, a 400.96% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$7.85M.
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.52M, a 51.19% increase from fiscal 2024.
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.01M, a 83.84% decline from fiscal 2023.
- UPSTREAM BIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $6.24M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $7.90M 10-Q · filed 2026-08-11 | $1.62M derived: sum of 3 quarters · filed 2026-08-11 | -$6.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $11.05M 10-Q · filed 2026-05-13 | $4.76M derived: sum of 2 quarters · filed 2026-05-13 | -$3.09M derived: sum of 3 quarters · filed 2026-05-13 | -$1.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$14.13M derived: sum of 2 quarters · filed 2026-03-26 | -$12.22M derived: sum of 3 quarters · filed 2026-08-11 | $1.52M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$7.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$5.93M derived: sum of 2 quarters · filed 2026-08-11 | $7.81M 10-Q · filed 2025-11-05 | $9.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $15.66M 10-Q · filed 2026-08-11 | $17.75M derived: sum of 3 quarters · filed 2026-08-11 | $17.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $13.74M 10-Q · filed 2026-05-13 | $15.83M derived: sum of 2 quarters · filed 2026-05-13 | $15.12M derived: sum of 3 quarters · filed 2026-05-13 | $13.05M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.38M derived: sum of 2 quarters · filed 2026-03-26 | -$694.00K derived: sum of 3 quarters · filed 2026-03-26 | $1.01M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$710.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.78M derived: sum of 2 quarters · filed 2025-11-05 | -$1.08M 10-Q · filed 2025-11-05 | $4.87M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$371.00K 10-Q · filed 2025-08-06 | $5.58M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $1.70M 10-Q · filed 2025-05-06 | $7.66M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $6.24M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $282.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |